PMV Pharmaceuticals, Inc.
PMVP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $32 | $32 | $0 | $0 |
| Gross Profit | -$32 | -$32 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $18,178 | $18,368 | $17,441 | $13,767 |
| G&A Expenses | $0 | $4,479 | $4,123 | $11,401 |
| SG&A Expenses | $4,312 | $4,479 | $4,123 | $11,401 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22,490 | $22,847 | $21,564 | $25,168 |
| Operating Income | -$22,522 | -$22,879 | -$21,564 | -$25,168 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,457 | $1,674 | $1,931 | $2,168 |
| Pre-Tax Income | -$21,065 | -$21,205 | -$19,633 | -$23,000 |
| Tax Expense | -$6 | $5 | -$2,197 | $0 |
| Net Income | -$21,059 | -$21,210 | -$17,436 | -$23,000 |
| % Margin | – | – | – | – |
| EPS | -0.397 | -0.41 | -0.34 | 0.37 |
| % Growth | 3.1% | -20.6% | -191.9% | – |
| EPS Diluted | -0.397 | -0.41 | -0.34 | 0.37 |
| Weighted Avg Shares Out | 52,993 | 52,011 | 51,952 | 51,574 |
| Weighted Avg Shares Out Dil | 52,993 | 52,011 | 51,952 | 51,574 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,480 | $1,690 | $1,935 | $2,287 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $32 | $32 | $37 | $39 |
| EBITDA | -$21,033 | -$21,173 | -$21,527 | -$25,129 |
| % Margin | – | – | – | – |